{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T03:24:27Z","timestamp":1784690667962,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Teijin Pharma Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Vessels"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s00380-024-02448-9","type":"journal-article","created":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T06:57:28Z","timestamp":1724050648000},"page":"111-122","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of the urate-lowering agent febuxostat in chronic heart failure patients with hyperuricemia: results from the LEAF-CHF study"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5470-6648","authenticated-orcid":false,"given":"Takashi","family":"Yokota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Kinugawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arata","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyoaki","family":"Murohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Tsutsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the LEAF-CHF Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,19]]},"reference":[{"key":"2448_CR1","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1093\/eurjhf\/hfp042","volume":"11","author":"C Bergamini","year":"2009","unstructured":"Bergamini C, Cicoira M, Rossi A, Vassanelli C (2009) Oxidative stress and hyperuricaemia: pathophysiology, clinical relevance, and therapeutic implications in chronic heart failure. Eur J Heart Fail 11:444\u2013452","journal-title":"Eur J Heart Fail"},{"key":"2448_CR2","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1093\/eurheartj\/ehq473","volume":"32","author":"GS Filippatos","year":"2011","unstructured":"Filippatos GS, Ahmed MI, Gladden JD, Mujib M, Aban IB, Love TE, Sanders PW, Pitt B, Anker SD, Ahmed A (2011) Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data. Eur Heart J 32:712\u2013720","journal-title":"Eur Heart J"},{"key":"2448_CR3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ijcard.2010.05.002","volume":"151","author":"S Hamaguchi","year":"2011","unstructured":"Hamaguchi S, Furumoto T, Tsuchihashi-Makaya M, Goto K, Goto D, Yokota T, Kinugawa S, Yokoshiki H, Takeshita A, Tsutsui H, Investigators J-C (2011) Hyperuricemia predicts adverse outcomes in patients with heart failure. Int J Cardiol 151:143\u2013147","journal-title":"Int J Cardiol"},{"key":"2448_CR4","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.amjcard.2014.09.008","volume":"114","author":"M Vaduganathan","year":"2014","unstructured":"Vaduganathan M, Greene SJ, Ambrosy AP, Mentz RJ, Subacius HP, Chioncel O, Maggioni AP, Swedberg K, Zannad F, Konstam MA, Senni M, Givertz MM, Butler J, Gheorghiade M, investigators Et (2014) Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial). Am J Cardiol 114:1713\u20131721","journal-title":"Am J Cardiol"},{"key":"2448_CR5","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1067\/mhj.2002.122122","volume":"143","author":"M Cicoira","year":"2002","unstructured":"Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Brighetti G, Zeni P, Zardini P (2002) Elevated serum uric acid levels are associated with diastolic dysfunction in patients with dilated cardiomyopathy. Am Heart J 143:1107\u20131111","journal-title":"Am Heart J"},{"key":"2448_CR6","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s11739-013-1016-9","volume":"9","author":"AF Cicero","year":"2014","unstructured":"Cicero AF, Rosticci M, Parini A, Baronio C, D\u2019Addato S, Borghi C (2014) Serum uric acid is inversely proportional to estimated stroke volume and cardiac output in a large sample of pharmacologically untreated subjects: data from the Brisighella Heart Study. Intern Emerg Med 9:655\u2013660","journal-title":"Intern Emerg Med"},{"key":"2448_CR7","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1161\/01.CIR.0000065637.10517.A0","volume":"107","author":"SD Anker","year":"2003","unstructured":"Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, Davos CH, Cicoira M, Shamim W, Kemp M, Segal R, Osterziel KJ, Leyva F, Hetzer R, Ponikowski P, Coats AJ (2003) Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 107:1991\u20131997","journal-title":"Circulation"},{"key":"2448_CR8","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1113\/jphysiol.2003.055913","volume":"555","author":"CE Berry","year":"2004","unstructured":"Berry CE, Hare JM (2004) Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol 555:589\u2013606","journal-title":"J Physiol"},{"key":"2448_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/eurjhf\/hfq178","volume":"13","author":"S Kobayashi","year":"2011","unstructured":"Kobayashi S, Susa T, Tanaka T, Wada Y, Okuda S, Doi M, Nao T, Yoshiga Y, Yamada J, Okamura T, Ueyama T, Kawamura S, Yano M, Matsuzaki M (2011) Urinary 8-hydroxy-2\u2019-deoxyguanosine reflects symptomatic status and severity of systolic dysfunction in patients with chronic heart failure. Eur J Heart Fail 13:29\u201336","journal-title":"Eur J Heart Fail"},{"key":"2448_CR10","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1016\/j.jacc.2007.02.053","volume":"49","author":"WH Tang","year":"2007","unstructured":"Tang WH, Tong W, Troughton RW, Martin MG, Shrestha K, Borowski A, Jasper S, Hazen SL, Klein AL (2007) Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. J Am Coll Cardiol 49:2364\u20132370","journal-title":"J Am Coll Cardiol"},{"key":"2448_CR11","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1038\/s41598-021-81736-0","volume":"11","author":"T Yokota","year":"2021","unstructured":"Yokota T, Kinugawa S, Hirabayashi K, Yamato M, Takada S, Suga T, Nakano I, Fukushima A, Matsushima S, Okita K, Tsutsui H (2021) Systemic oxidative stress is associated with lower aerobic capacity and impaired skeletal muscle energy metabolism in heart failure patients. Sci Rep 11:2272","journal-title":"Sci Rep"},{"key":"2448_CR12","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1161\/01.CIR.0000041431.57222.AF","volume":"106","author":"U Landmesser","year":"2002","unstructured":"Landmesser U, Spiekermann S, Dikalov S, Tatge H, Wilke R, Kohler C, Harrison DG, Hornig B, Drexler H (2002) Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 106:3073\u20133078","journal-title":"Circulation"},{"key":"2448_CR13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/j.1755-5922.2011.00277.x","volume":"30","author":"P Higgins","year":"2012","unstructured":"Higgins P, Dawson J, Lees KR, McArthur K, Quinn TJ, Walters MR (2012) Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis. Cardiovasc Ther 30:217\u2013226","journal-title":"Cardiovasc Ther"},{"key":"2448_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1136\/heart.87.3.229","volume":"87","author":"AD Struthers","year":"2002","unstructured":"Struthers AD, Donnan PT, Lindsay P, McNaughton D, Broomhall J, MacDonald TM (2002) Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart 87:229\u2013234","journal-title":"Heart"},{"key":"2448_CR15","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1111\/j.1742-1241.2009.02118.x","volume":"63","author":"L Wei","year":"2009","unstructured":"Wei L, Fahey T, Struthers AD, MacDonald TM (2009) Association between allopurinol and mortality in heart failure patients: a long-term follow-up study. Int J Clin Pract 63:1327\u20131333","journal-title":"Int J Clin Pract"},{"key":"2448_CR16","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/hrt.2004.040477","volume":"91","author":"AD Gavin","year":"2005","unstructured":"Gavin AD, Struthers AD (2005) Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure. Heart 91:749\u2013753","journal-title":"Heart"},{"key":"2448_CR17","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1161\/CIRCULATIONAHA.114.014536","volume":"131","author":"MM Givertz","year":"2015","unstructured":"Givertz MM, Anstrom KJ, Redfield MM, Deswal A, Haddad H, Butler J, Tang WH, Dunlap ME, LeWinter MM, Mann DL, Felker GM, O\u2019Connor CM, Goldsmith SR, Ofili EO, Saltzberg MT, Margulies KB, Cappola TP, Konstam MA, Semigran MJ, McNulty SE, Lee KL, Shah MR, Hernandez AF, Network NHFCR (2015) Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the xanthine oxidase inhibition for hyperuricemic heart failure patients (EXACT-HF) study. Circulation 131:1763\u20131771","journal-title":"Circulation"},{"key":"2448_CR18","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353:2450\u20132461","journal-title":"N Engl J Med"},{"issue":"8","key":"2448_CR19","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1253\/circj.CJ-13-0082","volume":"77","author":"A Sezai","year":"2013","unstructured":"Sezai A, Soma M, Nakata K, Hata M, Yoshitake I, Wakui S, Hata H, Shiono M (2013) Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial). Circ J 77(8):2043\u20132049","journal-title":"Circ J"},{"key":"2448_CR20","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1093\/eurheartj\/ehz119","volume":"40","author":"S Kojima","year":"2019","unstructured":"Kojima S, Matsui K, Hiramitsu S, Hisatome I, Waki M, Uchiyama K, Yokota N, Tokutake E, Wakasa Y, Jinnouchi H, Kakuda H, Hayashi T, Kawai N, Mori H, Sugawara M, Ohya Y, Kimura K, Saito Y, Ogawa H (2019) Febuxostat for cerebral and cardiorenovascular events prevention study. Eur Heart J 40:1778\u20131786","journal-title":"Eur Heart J"},{"key":"2448_CR21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ijcard.2021.11.076","volume":"349","author":"M Konishi","year":"2022","unstructured":"Konishi M, Kojima S, Uchiyama K, Yokota N, Tokutake E, Wakasa Y, Hiramitsu S, Waki M, Jinnouchi H, Kakuda H, Hayashi T, Kawai N, Sugawara M, Mori H, Tsujita K, Matsui K, Hisatome I, Ohya Y, Kimura K, Saito Y, Ogawa H, Febuxostat for Cardiorenovascular Events Prevention Study Investigators (2022) Effect of febuxostat on clinical outcomes in patients with hyperuricemia and cardiovascular disease. Int J Cardiol 349:127\u2013133","journal-title":"Int J Cardiol"},{"key":"2448_CR22","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1536\/ihj.17-560","volume":"59","author":"T Yokota","year":"2018","unstructured":"Yokota T, Fukushima A, Kinugawa S, Okumura T, Murohara T, Tsutsui H (2018) Randomized trial of effect of urate-lowering agent febuxostat in chronic heart failure patients with hyperuricemia (LEAF-CHF). Int Heart J 59:976\u2013982","journal-title":"Int Heart J"},{"key":"2448_CR23","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A, Collaborators developing the Japanese equation for estimated GFR, (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53:982\u2013992","journal-title":"Am J Kidney Dis"},{"key":"2448_CR24","unstructured":"Administartion USFaD (2017) FDA Drug Safety Communication: FDA to evaluate increased risk of heart-related death and death from all causes with the gout medicine febuxostat (Uloric) (https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-evaluate-increased-risk-heart-related-death-and-death-all-causes). Accessed 15 Nov 2017"},{"key":"2448_CR25","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","volume":"378","author":"WB White","year":"2018","unstructured":"White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L, Investigators CARES (2018) Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med 378:1200\u20131210","journal-title":"N Engl J Med"},{"key":"2448_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.770815","volume":"12","author":"K Si","year":"2021","unstructured":"Si K, Wei C, Xu L, Zhou Y, Lv W, Dong B, Wang Z, Huang Y, Wang Y, Chen Y (2021) Hyperuricemia and the risk of heart failure: pathophysiology and therapeutic implications. Front Endocrinol (Lausanne) 12:770815","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2448_CR27","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2165\/00003088-200645080-00005","volume":"45","author":"R Khosravan","year":"2006","unstructured":"Khosravan R, Grabowski BA, Wu JT, Joseph-Ridge N, Vernillet L (2006) Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects. Clin Pharmacokinet 45:821\u2013841","journal-title":"Clin Pharmacokinet"},{"key":"2448_CR28","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.3390\/jcm11092468","volume":"11","author":"Y Lee","year":"2022","unstructured":"Lee Y, Hwang J, Desai SH, Li X, Jenkins C, Kopp JB, Winkler CA, Cho SK (2022) Efficacy of xanthine oxidase inhibitors in lowering serum uric acid in chronic kidney disease: a systematic review and meta-analysis. J Clin Med 11:2468","journal-title":"J Clin Med"},{"key":"2448_CR29","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/ejhf.1056","volume":"20","author":"UM Mogensen","year":"2018","unstructured":"Mogensen UM, Kober L, Jhund PS, Desai AS, Senni M, Kristensen SL, Dukat A, Chen CH, Ramires F, Lefkowitz MP, Prescott MF, Shi VC, Rouleau JL, Solomon SD, Swedberg K, Packer M, McMurray JJV, PARADIGM-HF Investigators and Committees (2018) Sacubitril\/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF. Eur J Heart Fail 20:514\u2013522","journal-title":"Eur J Heart Fail"},{"key":"2448_CR30","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1016\/j.jacc.2008.01.068","volume":"51","author":"JM Hare","year":"2008","unstructured":"Hare JM, Mangal B, Brown J, Fisher C Jr, Freudenberger R, Colucci WS, Mann DL, Liu P, Givertz MM, Schwarz RP, Investigators OPT-CHF (2008) Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol 51:2301\u20132309","journal-title":"J Am Coll Cardiol"},{"key":"2448_CR31","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1002\/art.40583","volume":"70","author":"H Choi","year":"2018","unstructured":"Choi H, Neogi T, Stamp L, Dalbeth N, Terkeltaub R (2018) New perspectives in rheumatology: implications of the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities trial and the associated food and drug administration public safety alert. Arthritis Rheumatol 70:1702\u20131709","journal-title":"Arthritis Rheumatol"},{"key":"2448_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001944","volume":"8","author":"BZ Ghang","year":"2022","unstructured":"Ghang BZ, Lee JS, Choi J, Kim J, Yoo B (2022) Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial. RMD Open 8:e001944","journal-title":"RMD Open"},{"key":"2448_CR33","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/S0140-6736(20)32234-0","volume":"396","author":"IS Mackenzie","year":"2020","unstructured":"Mackenzie IS, Ford I, Nuki G, Hallas J, Hawkey CJ, Webster J, Ralston SH, Walters M, Robertson M, De Caterina R, Findlay E, Perez-Ruiz F, McMurray JJV, MacDonald TM, Group FS (2020) Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet 396:1745\u20131757","journal-title":"Lancet"}],"container-title":["Heart and Vessels"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-024-02448-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00380-024-02448-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-024-02448-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T15:06:08Z","timestamp":1737990368000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00380-024-02448-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,19]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["2448"],"URL":"https:\/\/doi.org\/10.1007\/s00380-024-02448-9","relation":{},"ISSN":["0910-8327","1615-2573"],"issn-type":[{"value":"0910-8327","type":"print"},{"value":"1615-2573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,19]]},"assertion":[{"value":"16 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was designed by the authors in collaboration with Teijin Pharma Ltd. and the contract research organization (Hubitgenomix Co., Tokyo), but Teijin Pharma Ltd. had no involvement in data collection, event evaluation, or data analysis. This study was supported by Hubitgenomix Co., and the first manuscript was written by Go Ichien, Naoto Minagawa, and Yasuhiko Koezuka (Hubitgenomix Co.). The manuscript was reviewed and revised by all the authors, and all authors approved the final manuscript.\u00a0H.T. has received lecture fees and donations from Teijin Pharma Ltd. The other authors declare no conflicts of interest relevant to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}